


Immunotoxicology Specialty Section Newsletter



IMMUNOTOXICOLOGY
SPECIALTY SECTION



2009 - 2010 Executive Committee

President

Dr. Jean Regal

Vice President

Dr. Leigh Ann Burns Naas

Vice President-Elect

Dr. Rodney R. Dietert

Secretary-Treasurer

Dr. Jacintha M. Shenton

Past President

Dr. Jeanine L. Bussiere

Senior Councilor

Dr. Marc Pallardy

Junior Councilor

Dr. Wendy J. Komocsar

Postdoc Representative

Dr. Stacey Anderson

Student Representative

Mr. Haitian Lu

The Immunotoxicology Specialty Section Newsletter is published three times/year (May, August and November). If you would like to share a book review, meeting report, web site, or any other item of interest with members of the Specialty Section, please send it to us by the middle of the month preceding the planned publication date. All comments on, or suggestions for, the newsletter are welcome.

Jacintha M. Shenton, Ph.D., Editor
jacintha.shenton@utoronto.ca (home)
shentonj@medimmune.com (work)

Typesetting / desktop publishing provided by
L. Peyton Myers, Ph.D., Co-Editor

President's Message

Jean Regal, Ph.D.

Celebrate 25 years of the ImTox SS in 2010!

Don't miss it! Salt Lake City, March 7-11, 2010

The ImTox SS began in 1985 so 2010 is our 25th year. In recognition, we will be celebrating at our specialty section reception at the 2010 SOT annual meeting in Salt Lake City.

SAVE THIS DATE and TIME:

ImTox SS Reception
Tuesday evening, March 9, 6 pm
Salt Lake City Convention Center



Dr. Jean Regal
President, ImTox SS
2009-2010

The celebration will include a slide show portraying the history of the ImTox SS. To make the slide show grand please contribute photographs. Look through your files and send any and all photographs of our members (both past and present) to Peyton Myers (Laine.Myers@fda.hhs.gov).

SEND PHOTOS from the 80s, 90s, and today!!

Before (past) and after (present) photographs would be highly appreciated. ☺

We hope that many of the Past Presidents of the specialty section will be able to attend the celebration so that we can recognize them for their service and properly celebrate the past 25 years and the years to come.

Donations to support the celebration are welcome. Checks can be made out to SOT (please indicate on the check that the monies are to support the 25th Anniversary Celebration) and sent to the ImTox SS Secretary/Treasurer, Dr. Jacintha Shenton, Aaron Klug Building, MedImmune, Granta Park, Cambridge, CB21 6GH, England.

Thank you and hope to see you there,

The 25th Anniversary Celebration planning committee: *Jean Regal, Leigh Ann Burns Naas, Rod Dietert, Jacintha Shenton, Jeanine Bussiere, Dori Germolec, Peyton Myers, Haitian Lu, and Stacey Anderson*

President's Message.....	pages 1-2
Committee Reports.....	pages 3-11
JSIT Meeting Report.....	pages 11-13
Announcements.....	pages 14-17
Recent Immunotoxicology Publications	pages 18-21

Contribute to the HESI Immunotoxicology Young Investigator Award Fund Today

Download the Endowment Donor Form here http://toxicology.org/AI/CSOT/Endowment_Donor_form.pdf or through the link on the ImTox SS webpage <http://www.toxicology.org/ISOT/SS/imtox/Index.asp> and contribute to the Health and Environmental Science Institute (HESI) Immunotoxicology Young Investigator Award Fund. Proceeds from the Fund will be used to assist a young investigator to attend and participate in the annual meeting of the SOT (see the Awards Committee report within this newsletter). Thanks to HESI for the initial contribution and Dr. Jeanine Bussiere for working so hard to get this fund established for young immunotoxicologists within 5 years of their doctoral dissertation. What better way to encourage up and coming immunotoxicologists to attend the SOT meeting and participate in our great specialty section.

Support for the SIEE Study Section

Thank you!! Sincere appreciation to all who took the time to send a letter of support to Dr. Garte for continuation of the Systemic Injury by Environmental Exposure (SIEE) Study Section for review of toxicology grants, including immunotoxicology. Steve Pruett's ad hoc committee (Steve Pruett, Norb Kaminski, Deborah Keil, Paige Lawrence, Judy Zelikoff, and Prakash Nagarkatti) also formulated a strong and convincing letter from the ImTox SS articulating the importance of SIEE for funding the strongest immunotoxicology research and continuing the training of immunotoxicologists.

ImTox SS Program Proposal Process Showcased

During September, SOT held a series of Leadership Connection webinars for specialty section leadership to assist the leadership in conducting the business of the specialty sections. Included in this series was a session on program proposal preparation for the SOT annual meeting. Because of the long term success of our specialty section in bringing great programs to the meeting, we were one of three specialty sections asked to outline the process for generating successful SOT program proposals. Leigh Ann Burns Naas represented our section and provided great information to the leadership of other sections on how to be successful. Thanks Leigh Ann!

Celebrate 25 years of the ImTox SS in 2010!
Don't miss it! Salt Lake City, March 7-11, 2010.

Program Committee Report



(rrd1@cornell.edu) no later than Friday December 11th, 2009.

Let's make 2011 and the 50th Anniversary of SOT a banner year for Immunotoxicology.

Submitted by: *Dr. Rod Dietert*

Please send your program proposals for the 2011 SOT annual meeting in Washington, DC, to Rod Dietert

Remember they can be in the form of Symposia, Roundtables, Continuing Education Courses, Historical Highlights or Informational Sessions. A brief description of each category is provided below:

Session Type	Subject Matter	Duration	Speakers
Symposium	Recent scientific advances	≤ 3 hours	4-5 (30-35 minutes each; Summary by last speaker)
Workshop	Emphasis on quality presentations of generally accepted, state-of-the-art knowledge in toxicology. Informal, interactive presentations with emphasis on discussion	≤ 3 hours	1-5
Continuing Education	Emphasis on quality presentations of generally accepted, state-of-the-art knowledge in toxicology	4 hr Sunrise, 1 hr	CE: 4-5 total Sunrise: 1
Roundtable	Controversial subjects	1.5 hr	3-5 (5 min statement with balance for discussion)
Historical Highlight	The selected topic should be broad based, include the contributions of multiple laboratories and feature a review of a historical body of science that has impacted the field of toxicology. The title should be descriptive of the advancement that has been achieved and/or the impact of the advancement	1.5 hr	Moderator and 1-3 speakers (lecture in symposium format with time for Q&A)
Informational Session	Not based on the outcome of scientific research. Should address informational needs of members on topics such as Career Development, General Information, and Planned Scientific Activities	1.5 or 2.75 hr (need to explain extended time need)	Number depends on duration. Short: 10-15 minutes each with the balance for discussion. Long: 3-5

Student and Postdoctoral Report




Submitted by
Dr. Stacey Anderson,
Postdoctoral Representative,
and Haitian Lu, Student
Representative

Greetings students and postdocs!
Exciting New Business!!!

ImTox SS 25th Anniversary Celebration

All student and postdoc members of the ImTox SS should have received an e-mail from Haitian about the ImTox SS 25th Anniversary Celebration. If you did not receive this e-mail, please send your e-mail address to the Editor, Jacintha Shenton (shentonj@medimmune.com), so that Jacintha can add you to the ImTox SS student/postdoc distribution list.

For those of you who did not receive the e-mail, inadvertently deleted it, or just simply ignored it, it went like this...




I am writing to request your contributions to a slide show that will be presented in celebration of the 25th Anniversary of the ImTox SS that will be taking place at the 2010 SOT annual meeting in Salt Lake City.



A 25th anniversary task force has been formed to plan the celebration of this historical event which will occur at the ImTox SS reception (the evening of Tuesday March 9th, 2010). The slide show will feature past award winners, past presidents, historical moments, and most importantly us...the student and postdoctoral members! Student and postdoctoral members are a vital component of our specialty section. Therefore, we are soliciting a personal photograph or photographs picturing our student and postdoc members engaged in either SOT activities or activities in your respective research labs. Please also write a few sentences telling us what made you become interested in immunotoxicology or choose immunotoxicology as your major area. These contributions will be compiled and included in the slide show. Be a part of history!

Please take a few minutes to send your photographs, the reason you love immunotox, and any other suggestions for the 25th anniversary celebration to Haitian Lu (luhaitian82@gmail.com). Don't make us use stickmen and women to represent you!



WANTED - New Student and Postdoc Representatives

Dr. Stacey Anderson completed her term as the ImTox SS postdoctoral representative in March 2009 and Haitian Lu will complete his term as the student representative in March 2010. Thus, it's time to pass the baton to the next generation of student and postdoc representatives. For those interested in these positions, please send your CV and a nomination letter from your advisor to Dr. Jean Regal (jregal@d.umn.edu) by Nov 30, 2009 or Dec 31, 2009 for the postdoctoral or student representative positions, respectively. You should first verify with your advisor that he/she is willing to fund your travel to SOT for the next two years. Please do not hesitate to contact Haitian (luhaitian82@gmail.com) or Stacey (sanderson4@cdc.gov) for more information about serving as a student or postdoctoral representative.

Student/Postdoctoral Reminders:



Be Recognized for the Star that you Are!

Please take note of the Awards Committee report within this newsletter. These awards present opportunities for students and postdocs to be recognized for their contributions to the field of Immunotoxicology. Award winners will be recognized at the 2010 ImTox SS reception, in the ImTox SS newsletter, and on the ImTox SS website.

Come ONE Come ALL!

If you missed the ImTox SS student/postdoc mixer in Baltimore don't despair, there will be a similar opportunity to socialize at the 2010 meeting in Salt Lake City (details to follow)! We look forward to seeing ALL OF YOU at the 2010 mixer. Should you have any suggestions about other types of events, please feel free to contact us, Stacey (sanderson4@cdc.gov) or Haitian (luhaitia@msu.edu).

Immunotoxicology Pool of Lecturers



Submitted by: Dr. Judy Zelikoff

The Immunotoxicology Pool of Lecturers Program, which allows faculty to invite immunotoxicology guest lecturers (see available individuals below) to teach in their class, has been running successfully over the last few years. Last year, Dr. Dave Shepherd asked for, and received, financial support from the Program for MaryJane Selgrade (US EPA) and Prakash Nagarkatti (Univ. of South Carolina) to teach at the University of Montana. MaryJane lectured on "environmental pollutants and allergic lung disease", while Prakash discussed "immunomodulation by natural products". Both lectures were a huge success.

If anyone is interested in having any of our expert Immunotoxicologists (see insert box) teach in one of your classes either during this Fall semester (2009) or in the upcoming Spring (2010) semester, please contact Judy (judith.zelikoff@nyumc.org) as soon as possible with the following information: (1) course title and academic level (i.e., undergraduate, graduate, postdoctoral/medical); (2) name of guest lecturer and the topic to be presented; (3) amount and purpose of requested funds; and, (4) date needed. Once received, your request will be discussed by the ImTox SS President and Secretary/Treasurer and prioritized (if requests are made from multiple schools). After a final decision is reached, you will be notified of the decision (within about a month) and the amount of financial support you will receive.

The amount of funds available for any given year is related to the specialty section budget. Monies from the program can be used to support guest lecturer travel, hotel accommodations for a single night, and/or meals. We look forward to hearing from you.

If you want to go on the list as a guest lecturer, please write to Judy at Judith.zelikoff@nyumc.org. Thanks.

Immunotoxicology Pool of Lecturers

Judy Zelikoff (Organizer)
Leigh Ann Burns Naas
Mitch Cohen
George DeGeorge
Rod Dietert
Ken Draper
Deborah Finco-Kent
Kathleen Gilbert
Ken Hastings
Robert House
Norb Kaminski
Barb Kaplan

Nancy Kerkvliet
Ian Kimber
Raj Krishnaraj
David Lawrence
Mike McCabe
Mitzi Nagarkatti
Prakash Nagarkatti
Margie Peden-Adams
Joseph Piccotti
Helen Ratajczak
Jean Regal
MaryJane Selgrade

Financial Report

Submitted by: Dr. Jacintha Shenton



The fiscal year runs for 12 months ending on June 30th

	2008-2009	2007-2008
Ordinary Income/Expense		
Income		
Contributions	900	-
Dues	4,725	4,575
Registration	4,009	4,516
Interest	456	789
	-----	-----
Total Income	10,090	9,881
	-----	-----
Expense		
Awards - Sections	900	900
Plaques (accent engraving)	727	741
Executive Meetings	1,622	2,700
Miscellaneous	1,846	2,351
Newsletter	350	400
Reception	10,156	4,581
	-----	-----
Total Expense	15,602	11,674
	-----	-----
Excess (Deficiency) of		
 Revenue over Expenses	(5,512)	(1,793)
	-----	-----
Net Assets Beginning of year	16,576	18,369
	-----	-----
Net Assets End of Year	11,064	16,576
	=====	=====


All entries are listed in US Dollars and are rounded to the nearest dollar. Income includes dues (paid with your SOT membership) and registration (which is based on the number of ImTox SS members at the SOT annual meeting).

Expenses include the Imtox SS Executive Meeting & Reception held at the SOT annual meeting, miscellaneous expenses (monies for the ImTox Pool of Lecturer's, the Japan Exchange, and the Student/Postdoc mixer), and the newsletter (typesetting).


ImTox SS Membership Committee Report

Submitted by: Dr. George DeGeorge

By Membership Category




By Organization Category




NP: Not for Profit

CRO: Contract Research Organization

ImTox SS Membership Committee Report



Note: The “dip” occurs when SOT deletes those who haven’t renewed at the end of the year.



Awards Committee Update



Submitted by:
Dr. Marc Pallardy

The ImTox SS is requesting nominations for the following awards to be recognized at the 2010 SOT annual meeting:

ImTox SS Vos Award — Career Achievement in Immunotoxicology

This award is offered as recognition to a Senior Investigator whose body of work represents an outstanding achievement in immunotoxicology. The nominator should provide a discussion of the role that the individual's work has played in advancing the field of immunotoxicology. A curriculum vitae and bibliography for the nominee should also be included. A second letter of recommendation from another investigator in the field would be helpful. Nominees are evaluated with respect to the following criteria:

- 1) Contribution to the field of immunotoxicology—depth and breadth of scientific contributions and significance of contributions for advancing the field;
- 2) Major influence in the education/training/mentorship of young scientists in the field of immunotoxicology including

training in government, industry, or academia;

3) Leadership and service to the immunotoxicology field including involvement in the specialty section or other meetings/organizations related to immunotoxicology;

4) Influence on regulatory and risk/safety assessment decisions related to immunotoxicology.

Nominations of unsuccessful candidates will be considered for two additional years unless the nomination is withdrawn by the sponsor. Final decisions will be made by the Nominating Committee (President, last three Past Presidents, the Vice President, and Vice President-elect).

Nominations should be submitted by December 30, 2009 to Dr. Jean Regal [E-mail: jregal@d.umn.edu]

ImTox SS Best Paper of the Year Award

An engraved plaque will be awarded to the author(s) of the best paper in the area of immunotoxicology, published in ANY peer-reviewed journal. The paper must have been published between July 1, 2008 and Dec 31, 2009. The nomination for this award should provide a full citation of the paper and a short discussion of the value of the research to the field of immunotoxicology. Authors may

not self-nominate their own papers. Review papers are not eligible for this award.

Decisions on this award will be made by members of the Awards Committee, chaired by the Senior Councilor.

Nominations should be submitted by February 1, 2010 to Dr. Marc Pallardy [E-mail: marc.pallardy@u-psud.fr]

ImTox SS Outstanding Young Immunotoxicologist Award

An engraved plaque will be awarded to the young investigator whose body of work has made significant contributions to the field of Immunotoxicology. This award is NOT LIMITED to those in academia. Investigators who have had an impact on regulatory issues or within industry will also be considered.

The nominee must have less than ten years of experience since obtaining their highest degree. Exceptions to the 10 year limitation can be made if careers have been interrupted for family or health reasons, or clinical practice, etc. Reasons for the exception should be documented in the nomination letter.

Nominators are required to document the contributions of the candidate and also provide a curriculum vitae and bibliography of the candidate. The depth, breadth and significance of the

scientific contributions of the nominee to advancing the field of immunotoxicology should be addressed, as well as service to the immunotoxicology community.

All nominations of candidates that have not received the award will be retained and considered for an additional 2 years unless the nomination is withdrawn by the sponsor.

Determination of the awardee will be by the Vice President and members of the Awards Committee.

Nominations should be submitted by January 15, 2010 to Dr. Leigh Ann Burns Naas [E-mail: leighann.burns@pfizer.com]

ImTox SS Best Presentation by a Postdoctoral Trainee Award

The award requirements are submission of a complete written version (including all graphs and tables) of an immunotoxicology presentation to be made at the 2010 SOT Annual Meeting.

This presentation is to be accompanied by a letter of nomination from the postdoctoral trainee's advisor. Please utilize electronic submissions.

No manuscripts will be accepted.

Winners will receive a plaque and cash award.

We encourage you to take a minute to nominate your postdoctoral trainees so they can be recognized for their work.

Nominations should be submitted by February 1, 2010 to Dr. Marc Pallardy [E-mail: marc.pallardy@u-psud.fr]

ImTox SS Best Presentation by a Student Award

The award requirements are submission of a complete written version (including all graphs and tables) of an immunotoxicology presentation to be made at the 2010 SOT Annual Meeting.

- This presentation is to be accompanied by a letter of nomination from the student's advisor. Please utilize electronic submissions.
- No manuscripts will be accepted.
- Winners will receive a plaque and cash award

We encourage you to take a minute to nominate your students and so they can be recognized for their work.

Nominations should be submitted by February 1, 2010 to Dr. Marc Pallardy [E-mail: marc.pallardy@u-psud.fr]

ImTox SS HESI Immunotoxicology Young Investigator Travel Award

The HESI Immunotoxicology Young Investigator Travel Award will be awarded each year to a young investigator who is within 5 years of receiving a Ph.D. degree. This award was made possible through the hard work of Dr. Jeanine Bussiere, Past President, and HESI. This award replaces the International Postdoc Award and will provide a cash award to assist young investigators to attend SOT and present their research. Please contribute to this fund and take any advantage of employer and SOT matching funds while they last!

The guidelines for this award are:

- <5 years from having completed his/her graduate dissertation.
- Letter from postdoctoral advisor and/or employer indicating the individual's past contributions to immunotoxicology (or a closely-related discipline) and potential future contributions to the discipline.
- Curriculum Vitae
- Letter from applicant on how attendance at SOT will contribute to their career development in immunotoxicology.

- The individual must have submitted an abstract and be able to attend the Annual Meeting.
- The abstract must be included in the application.
- Both U.S. and International individuals are eligible.
- The individual need not be a member of SOT, but those who are members or who are in the process of becoming members will be given preferential consideration.
- Selection of the recipient will be made by a committee consisting of the Vice President-elect, Vice President, President, and most recent three Past-Presidents. An individual cannot be the recipient of the award more than once.

Please submit nominations for the HESI Immunotoxicology Young Investigator Travel Award by December 30 2009 to: Dr. Jean Regal [E-mail: jregal@d.umn.edu].

This award is made possible by the Health and Environmental Science Institute (HESI) Immunotoxicology Young Investigator Student Award Fund of the SOT Endowment.

The Imtox SS Report from the 16th Annual Meeting of the Japanese Society of Immunotoxicology

*Asahikawa, Japan
August 27-28, 2009*

Submitted by: Drs. Dori Germolec and Judith Zelikoff

As part of the ongoing cooperation and scientific interchange that the ImTox SS has with the Japanese Society of Immunotoxicology (JSIT), we (Judy and Dori) were chosen to represent our specialty Section at the 16th Annual Meeting of the JSIT. The theme for this year's meeting, held in the beautiful city of Asahikawa on the Island of Hokkaido, was "Children and Immunity".

We arrived in Tokyo on the 25th of August and were whisked to our hotel near the Haneda airport. There we were met by one of our hosts for this journey, Dr. Kazuichi Nakamura, who introduced us to Tokyo and the wonders of Japanese noodle soup. On the 26th we joined Dr. Nakamura and a large group of JSIT members for the flight from Tokyo to Asahikawa. Hokkaido is a volcanic island, and on our journey to Asahikawa we were treated to spectacular mountain views and given a taste of the

beautiful gardens that front local homes and farms. That evening we joined our hosts for the JSIT conference opening dinner. Dr. Takahiko Yoshida, from the Asahikawa Medical College and President and Organizer of the 16th Annual Meeting, and the Executive Committee welcomed us. The dinner was an excellent opportunity for us to have wonderful Japanese cuisine and discuss current and future collaborations between the JSIT and the ImTox SS.

Dr. Yoshida opened the meeting on Thursday morning, and the sessions began with oral presentations on the effects of environmental chemicals on allergic and infectious disease. In a session chaired by Dr. Yoshida, Dori presented the first special lecture of the meeting entitled "Does immunomodulation early in life increase disease risk in children and beyond?" Oral presentations continued in the early afternoon in a session chaired by Dr. Yasuhide Kouchi and focused on novel methods in immunotoxicity. The meeting theme was highlighted in a symposium entitled, "Children and Immunity" chaired by Drs. Fujio Kayama and Dr. Kazuichi Nakamura. The symposium featured presentations by Dr. Sho Ishikawa on the breakdown of mucosal immunity in the gut and allergic sensitization by dioxins,

Dr. Chisato Mori on a health examination system to prevent fetal exposure to persistent organic pollutants and atopic dermatitis in infants, and Judy on how prenatal exposure to cigarette smoke increases tumor susceptibility of juvenile mice via changes in anti-tumor mechanisms. That evening, the JSIT hosted a wonderful dinner reception at the Asahikawa Grand Hotel. We were fortunate that Dr. Takemi Otsuki was willing to perform his “Song for the JSIT”

which he debuted at an earlier JSIT meeting. It was a treat to see old friends, begin new collaborations and hear about the exciting sessions being planned for both the 49th Annual Meeting of the SOT in Salt Lake City in March 2010 and the 17th Annual Meeting of the JSIT in Tsukuba in September 2010.

The second day featured a special lecture chaired by Dr. Jun-ichi Sawada and presented by Dr. Masao Kosuge, the Director

Emeritus of the Asahikawa Asahiyama Zoo regarding the role of the Asahiyama Zoo in education and species preservation. We were fortunate to get an “up close and personal” view of the zoo and all of its inhabitants that afternoon. The afternoon Workshop focused on “Standardization of an immunotoxicity test: T cell-dependent antibody response to keyhole limpet hemocyanin.” Oral and poster presentations highlighted the outstanding



Immunotoxicologists at the 16th Annual JSIT Meeting

Back Row: Fujio Kayama, Dori Germolec, Yasuhide Kouchi, Qing Li, Judy Zelikoff
Front Row: Takahiko Yoshida

contributions of our Japanese colleagues in all aspects of immunotoxicology.

After the meeting, we were entertained by Dr. Yoshida who brought us up to the mountains for a visit to Daisetsuzan National Park and its volcanic hot springs, followed by a wonderful Japanese meal with many of our meeting colleagues. Our flight back to Tokyo from Asahikawa was just the beginning of another

adventure, in which we traveled through the Ginza and up to the top of the Tokyo Tower. Dr. Nakamura acted as our tour guide for a final day in Tokyo, where we saw the Great Buddha of Kamakura, the port of Yokohama and its magnificent Chinatown, as well as beautiful shrines and temples. Our discussions on immunotoxicology and future collaborations did not end until we stepped on the plane headed back to New York.

We would like to sincerely thank all of our hosts in Japan for their warmth, welcome and kindness. We had many fruitful discussions about the future of our specialty section and toxicology in general. The hospitality that was extended to us was remarkable and made our trip a never to be forgotten experience. We look forward to continued collaborations with our JSIT colleagues.



Immunotoxicologists at the 16th Annual JSIT Meeting

Back Row: Hiroyuki Kojima, Fujio Kayama, Jun-ichi Sawada, Judy Zelikoff, Reiko Teshima, Yoshihiko Nakaki,
Front Row: Takahiko Yoshida, Dori Germolec

informa
PHARMACEUTICAL SCIENCE

INDEXED
IN
MEDLINE



Editor-in-Chief:

Mitchell D. Cohen, Ph.D.

New York University School of Medicine
Nelson Institute of Environmental Medicine
57 Old Forge Road, Tuxedo, NY 10987, USA
E-mail: mitchell.cohen@nyumc.org

Associate Editors:

Donald E. Gardner - Inhalation Toxicology Associates, Savannah GA, USA

Kenneth L. Hastings - Sanofi-Aventis, Corporate Regulatory Affairs, Bethesda, MD, USA

Robert V. House - DynPort Vaccine Company LLC, Frederick, MD, USA

Robert W. Luebke - National Health and Environmental Effects Research Laboratory, NC, USA

Jean F. Regal - University of Minnesota, Duluth, MN, USA

Kazuichi Nakamura - Shionogi & Co. Ltd, Tokyo, Japan

Henk Van Loveren - National Institute of Public Health and the Environment, Bilthoven, Netherlands

Abstracted/indexed in: Academic Search Complete, BIOBASE, EMBASE, EMBIOLOGY, Immunology Abstracts, MEDLINE, PubMed, SCOPUS, Toxicology Abstracts

Publication 2009

Volume: 6, 4 issues a year

Print ISSN: 1547-691X

Online ISSN: 1547-6901

MDxxxx

NOW
INVITING
SUBMISSIONS

Journal of Immunotoxicology

The Journal of Immunotoxicology is inviting submissions of manuscripts that cover the following subdisciplines of immunotoxicology:

- immunology
- toxicology
- molecular immunotoxicology
- developmental immunotoxicology
- pulmonary immunotoxicology
- regulatory immunotoxicology
- nutritional immunotoxicology
- mechanistic immunotoxicology
- wildlife immunotoxicology
- environmental immunotoxicology

All peer-reviewed, accepted articles are published both in print and online editions of the journals – ensuring your research is instantly accessible to an international community of immunotoxicologists, immunologists and toxicologists working in academia, government, consulting and industry.


Free color for online figures and tables now available!

Recently-published papers:

- **Testing Human Biologicals in Animal Host Resistance Models** - Gary R. Bureson and Florence G. Bureson
- **Pathogenic Role of Environmental Toxins in Immune-Mediated Liver Diseases** - Carmen Stanca, Jawad Babar, Vineet Singal, Esra Ozdenerol, and Joseph Odin
- **Changes in Gene Expression Induced by Carbamazepine and Phenytoin: Testing the Danger Hypothesis** - Wei Lu, Xujian Li, and Jack P. Uetrecht
- **The Latent Form of TGFB1 is Induced by TNF Through an ERK-Specific Pathway and is Activated by Asbestos-Derived Reactive Oxygen Species In Vitro and In Vivo** - Deborah E. Sullivan, MaryBeth Ferris, Derek Pociask, and Arnold R. Brody
- **Development of Interleukin-1 Receptor Antagonist Mutants with Enhanced Antagonistic Activity In Vitro and Improved Therapeutic Efficacy in Collagen-Induced Arthritis** - Eva Dahlen, Karin Barchan, Daniel Herrlander, Patrik Hojman, Marie Karlsson, Lill Ljung, Mats Andersson, Eva Beckman, Ann-Christin Malmborg Hager, Bjorn Walse, Leo Joosten, and Wim van den Berg
- **Interactions between B-Lymphocytes and Type 1 NKT Cells in Autoimmune Diabetes** - Francois D. Dufour, Pablo A. Silveira, and Alan G. Baxter
- **Effect of Polycyclic Aromatic Hydrocarbons and Carbon Black Particles on Pro-Inflammatory Cytokine Secretion: Impact of PAH Coating Onto Particles** - S. Goulaouic, L. Foucaud, A. Bennasroune, P. Laval-Gilly, and J. Falla

SUBMIT
YOUR
MANUSCRIPT
NOW

Submit your manuscript now at
www.informapharmascience.com/imt



**BRISTOL-MYERS SQUIBB COMPANY
PHARMACEUTICAL RESEARCH INSTITUTE
IMMUNOTOXICOLOGY
DRUG SAFETY EVALUATION
NEW BRUNSWICK, NEW JERSEY**

Employment Opportunity

The Immunotoxicology Department within Drug Safety Evaluation at Bristol-Myers Squibb Co., which is relocating from Syracuse, NY to New Brunswick, NJ, is seeking an independently thinking, highly motivated scientist with mechanistic and investigative experience in the assessment of alterations in immune status and function. Placement will be commensurate with the level of experience, but the ideal candidate will have a Ph.D. or equivalent and research background in immunology and/or immunotoxicology/immunopharmacology and a comprehensive knowledge of animal and human biology/physiology. The candidate should also have effective written and oral communication skills and the ability to manage multiple research activities. This person would be responsible for the scientific and toxicologic evaluation of selected drug candidates, such as immunomodulators and protein therapeutics; design and coordinate mechanistic and toxicology studies to support project and discovery working groups; and develop mechanistic approaches and utilize molecular and emerging technology platforms to address toxicity issues that arise, particularly those associated with the immune system.

Please submit letters of interest as well as academic credentials, relevant scientific publications and laboratory/research experience, and contact information for supporting references via e-mail, fax, or US mail to:

Dr. Helen G. Haggerty
Department of Immunotoxicology
Drug Safety Evaluation
Pharmaceutical Research Institute
Bristol-Myers Squibb Company
6000 Thompson Road, Mailstop J-4
East Syracuse, NY 13057
Fax- 315-432-2295
Email- helen.haggerty@bms.com

Bristol-Myers Squibb is an Equal Opportunity Employer.



European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

**WORKSHOP:
 IN VITRO CYTOKINE RELEASE ASSAYS TO PREDICT
 CYTOKINE RELEASE SYNDROME:
 THE CURRENT STATE-OF-THE-SCIENCE**

**To be held at the European Medicine Agency, London
 November 19, 2009**

9:00	Introductions and Welcome	<u>Beatriz Silva Lima</u> , Chairperson SWP EMA (10')
9:10	Key Note Speaker Clinical Features of Infusion Reactions / Cytokine Release Syndrome	<u>Hermann Einsele</u> , University of Wurzburg, Germany (30')
9:40	Key Note Speaker Mechanism of Infusion Reactions / Cytokine Release Syndrome	<u>Andrew George</u> , Imperial College London, England (30')
10:10	Optimisation of cytokine release assays for unwanted intrinsic activities of medicines	<u>Stephen Poole</u> , NIBSC, England (20')
10:30	Use of flow cytometry for investigating immunomodulatory effects of medicines	<u>Richard Stebbings</u> , NIBSC, England (20')
10:50	Cytokine release assays - the PEI perspective	<u>Jan Meuller Berghaus</u> , Paul Erlich Institute, Germany (20')
11:10	Coffee Break	
11:30	Evaluation of the Soluble and Solid Phase Cytokine Release Assay	<u>Jing Min</u> , Pfizer, St. Louis, MO (20')
11:50	A Novel In Vitro System to Assess Reactogenic Effects of Biologic Agents	<u>Padma Narayanan</u> , Amgen, Seattle, WA (20')

Announcements

12:10	Title to be provided	<u>Speaker TBD from Abstracts Submitted</u>
12:30	Development, validation and regulatory approval of a cytokine release test for contaminants	<u>Peter Bruger</u> , Novartis, Switzerland (20')
12:50	Questions for speakers	(10')
13:00	Lunch and Poster Review	(60')
14:00	Challenges with Using in vitro Assays to Predict Cytokine Release Syndrome	<u>Huub Schellekens</u> , Utrecht University, The Netherlands (15')
14:15	Open Discussion Session Challenges, Future Research Needs	Moderator: <u>Robin Thorpe</u> – NIBSC, England (90')
15:45	Coffee Break and Poster Review Development of Meeting conclusions and list of recommendations by the Planning Committee	(45')
16:30	Summary of the meeting conclusions and recommendation	<u>Jan Willem van der Laan</u> EMEA (30')
17:00	Close	

Planning Committee

Jan Willem van der Laan

Marc Pallardy

Jan Mueller-Berghaus

Stephen Poole

Robin Thorpe

Huub Schellekens

Karin Cederbrant

Thomas Kawabata

Jean Marc Vidal

http://www.emea.europa.eu/pdfs/conferenceflyers/EMEA_CRA_Agenda.pdf

Compiled by Haley Neff-LaFord.

ANYTIME you have a new **fully published** article to report, please send it to the coordinator, Haley Neff-LaFord: hnlaford@seagen.com

Asthma, Allergy, Autoimmunity & Hypersensitivity

Ayehunie S, Snell M, Child M and Klausner M. A plasmacytoid dendritic cell (CD123+/CD11c-) based assay system to predict contact allergenicity of chemicals. *Toxicology* 264:1-9, 2009.

Corsini E, Mitjans M, Galbiati V, Lucchi L, Galli CL and Marinovich M. Use of IL-18 production in a human keratinocyte cell line to discriminate contact sensitizers from irritants and low molecular weight respiratory allergens. *Toxicol In Vitro* 23:789-96, 2009.

De Jong WH, Arts JHE, De Klerk A, Schijf MA, Ezendam J, Kuper CF and Van Loveren H. Contact and respiratory sensitizers can be identified by cytokine profiles following inhalation exposure. *Toxicology* 263:103-111, 2009.

Gusareva ES, Bragina EJ, Buinova SN, Chernyak BA, Puzyrev VP, Ogorodova LM and Lipoldová M. Chromosome 12q24.3 controls sensitization to cat allergen in patients with asthma from Siberia, Russia. *Immunol Lett* 125:1-6, 2009.

Ladics GS and Selgrade MK. Identifying food proteins with allergenic potential: evolution of approaches to safety assessment and research to provide additional tools. *Reg Toxicol Pharmacol* 54:S2-S6, 2009.

Wang G, Wang J, Ma H and Khan MF. Increased nitration and carbonylation of proteins in MRL+/+ mice exposed to trichloroethene: potential role of protein oxidation in autoimmunity. *Toxicol Appl Pharmacol* 237:188-195, 2009.

White JML, White IR, Kimber I, Basketter DA, Buckley DA and McFadden JP. Atopic dermatitis and allergic reactions to individual fragrance chemicals. *Allergy* 64:312-316, 2009.

Developmental Immunotoxicology

Doherty-Lyons SP, Grabowski J, Hoffman C and Zelikoff JT. Early life insult from cigarette smoke may be predictive of chronic diseases later in life. *Biomarkers* 114:102-106, 2009.

Pilones K, Tatum A and Gavalchin J. Gestational exposure to mercury leads to persistent changes in T-cell phenotype and function in adult DBF1 mice. *J Immunotoxicol* 6:161-170, 2009.

Van Der Ven LTM, Van De Kuil T, Leonards PEG, Slob W, Lilienthal H, Litens S, Herlin M, Hakansson H, Canton RF, Van Den Berg M, Visser TJ, Van Loveren H, Vos JG and Piersma AP. Endocrine effects of hexabromocyclododecane (HCDB) in a one-generation reproduction study in Wistar rats. *Toxicol Lett* 185:51-62, 2009.

Effects: Compounds

Choi HJ, Yang H, Park SH and Moon Y. HuR/ELAVL1 RNA binding protein modulates interleukin-8 induction by muco-active ribotoxin deoxynivalenol. *Toxicol Appl Pharmacol* 240:46-54, 2009.

Dearman RJ, Betts CJ, Beresford L, Bailey L, Caddick HT and Kimber I. Butyl benzyl phthalate: effects on immune responses to ovalbumin in mice. *J Appl Toxicol* 29:118-125.

Kim ID and Ha BJ. Paeoniflorin protects RAW 264.7 macrophages from LPS-induced cytotoxicity and genotoxicity. *Toxicol In Vitro* 23:1014-1019, 2009.

Moon Y, Yang H and Park SH. Hypo-responsiveness of interleukin-8 production in human embryonic epithelial intestine 407 cells independent of NF-kappaB pathway: new lessons from endotoxin and ribotoxic deoxynivalenol. *Toxicol Appl Pharmacol* 231:94-102, 2009.

Osman AM, van Kol S, Peijnenburg A, Blokland M, Pennings JLA, Kleinjans JCS and van Loveren H. Proteomic analysis of mouse thymoma EL4 cells treated with bis(tri-n-butyltin)oxide (TBTO). *J Immunotoxicol* 6:174-183, 2009.

Park EJ, Yoon J, Choi K, Yi J and Park K. Induction of chronic inflammation in mice treated with titanium dioxide nanoparticles by intratracheal instillation. *Toxicology* 260:37-46, 2009.

Qazi MR, Bogdanska J, Butenhoff JL, Nelson BD, DePierre JW and Abedi-Valugerdi M. High-dose, short-term exposure of mice to perfluorooctanesulfonate (PFOS) or perfluorooctanoate (PFOA) affects the number of circulating neutrophils differently, but enhances the inflammatory responses of macrophages to lipopolysaccharide (LPS) in a similar fashion. *Toxicology* 262:207-214, 2009.

Qazi MR, Xia Z, Bogdanska J, Chang SC, Ehresman DJ, Butenhoff JL, Nelson BD, DePierre JW and Abedi-Valugerdi M. The atrophy and changes in the cellular compositions of the thymus and spleen observed in mice subjected to short-term exposure to perfluorooctanesulfonate are high-dose phenomena mediated in part by peroxisome proliferator-activated receptor-alpha (PPAR α). *Toxicology* 260:68-76, 2009.

Schellenberger MT, Grova N, Willième S, Farinelle S, Prodhomme EJF and Muller CP. Modulation of Benzo [a]pyrene induced immunotoxicity in mice actively immunized with a B[a]P-diphtheria toxoid conjugate. *TAAP* 240:37-45, 2009.

Tangjarukij C, Navasumrit P, Judith T, Zelikoff JT and Ruchirawat M. The effects of pyridoxine deficiency and supplementation on hematological profiles, lymphocyte function, and hepatic cytochrome P450 in B6C3F1 mice. *J Immunotoxicol* 6:147-160, 2009.

Tomiyama K, Yamaguchi A, Kuriyama T and Arakawa Y. Analysis of mechanisms of cell death of T-lymphocytes induced by organotin agents. *J Immunotoxicol* 6:184-193, 2009.

Uto T, Akagi T, Hamasaki T, Akashi M and Baba M. Modulation of innate and adaptive immunity by biodegradable nanoparticles. *Immunol Lett* 125:46-52, 2009.

Recent Immunotoxicology Publications

Verhagen H, Boekhorst J, Kamps L, Van Lieshout MJ, Ploeger H, Verreth D, Salminen S and Van Loveren H. Novel foods: an exploratory study into their grey area. *Br J Nutr* 28:1-8, 2009.

Waché YJ, Hbabi-Haddioui L, Guzylack-Piriou L, Belkhefha H, Roques C and Oswald IP. The mycotoxin Deoxynivalenol inhibits the cell surface expression of activation markers in human macrophages. *Toxicology* 262:239-244, 2009.

Yang H, Choi HJ, Park SH, Kim JS and Moon Y. Macrophage inhibitory cytokine-1 (MIC-1) and subsequent urokinase-type plasminogen activator mediate cell death responses by ribotoxic anisomycin in HCT-116 colon cancer cells. *Biochem Pharmacol* 78:1205-13, 2009.

General Immunotoxicology

Dearman RJ, Cumberbatch M, Maxwell G, Basketter DA and Kimber I. Toll-like receptor ligand activation of murine bone marrow-derived dendritic cells. *Immunology* 126:475-484, 2009.

Funatake CJ, Ao K, Suzuki T, Murai H, Yamamoto M, Fujii-Kuriyama Y, Kerkvliet NI and Nohara K. Expression of constitutively-active aryl hydrocarbon receptor in T-cells enhances the down-regulation of CD62L, but does not alter expression of CD25 or suppress the allogeneic CTL response. *J Immunotoxicol* 6:194-203, 2009.

Kerkvliet NI, Stepan LB, Vorachek W, Oda S, Farrer D, Wong CP, Pham D and Mourich DV. Activation of aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin prevents the development of diabetes in NOD mice and increases the frequency of CD4+CD25+Foxp3+ cells. *Immunotherapy* 1:539-547, 2009.

Quinn MJ, Jr., McFarland CA, LaFiandra EM and Johnson MS. A preliminary assessment of relative sensitivities to foreign red blood cell challenges in the northern bobwhite for potential evaluation of immunotoxicity. *J Immunotoxicol* 6:171-173, 2009.

Yang H, Park SH, Choi HJ and Moon Y. Epithelial cell survival by activating transcription factor 3 (ATF3) in response to chemical ribosome-inactivating stress. *Biochem Pharmacol* 77:1105-15, 2009.

Methods

Casati S, Aeby P, Kimber I, Maxwell G, Ovigne JM, Roggen E, Rovida C, Tosti L and Basketter D. Selection of chemicals for the development and evaluation of in vitro methods for skin sensitization testing. *Altern Lab Anim* 37:305-312, 2009.

Dearman RJ and Kimber I. Animal models of protein allergenicity: potential benefits, pitfalls and challenges. *Clin Exp Allergy* 39:458-468, 2009.

Verstraelen S, Nelissen I, Hooyberghs J, Witters H, Schoeters G, Van Cauwenberge P and Van Den Heuvel R. Gene profiles of THP-1 macrophages after in vitro exposure to respiratory (non-)sensitizing chemicals: Identification of discriminating genetic markers and pathway analysis. *Toxicol In Vitro* 23:1151-1162, 2009.

Reviews, Book Chapters, Commentaries

Basketter DA, McFadden JP, Gerberick GF, Cockshott A and Kimber I. Nothing is perfect, not even the local lymph node assay: a commentary and implications for REACH. *Contact Derm* 60:65-69, 2009.

Cressman R and Ladies GS. Further evaluation of the utility of "sliding window" FASTA in predicting cross-reactivity with allergenic proteins. *Reg. Toxicol Pharmacol* 54:S20-S25, 2009.

Dearman RJ, Betts CJ, Caddick HT and Kimber I. Cytokine profiling of chemical allergens in mice: impact of mitogen on selectivity of response. *J Appl Toxicol* 29:233-241, 2009.

Kimber I, Cumberbatch M and Dearman RJ. Langerhans cell migration: not necessarily always at the center of the skin sensitization universe. *J Invest Derm* 129:1852-1853, 2009.

Ladies GS. Food processing and allergenicity. *Mol Nutr Food Res* 53:945, 2009.

McFadden JP, White JML, Basketter DA and Kimber I. Does hapten exposure predispose to atopic disease? The hapten-atopy hypothesis. *Trends in Immunol* 30:67-74, 2009.

Mishra KP. Lead exposure and its impact on immune system: A review. *Toxicol In Vitro* 23:969-972, 2009.

Ng SP, Yoshido K and Zelikoff JT. Host resistance tumor challenge assays. In: *Techniques in Immunotoxicology* (R. Dietert, Ed.) Informa Press. 2009.

Park MV, Lankveld DP, van Loveren H and de Jong WH. The status of in vitro toxicity studies in the risk assessment of nanomaterials. *Nanomed* 4:669-685, 2009.

Selgrade MK, Bowman CC, Ladies GS, Privalle L and Laessig SA. Safety assessment of biotechnology products for potential risk of food allergy: implications of new research. *Toxicol Sci* 110:31-39, 2009.

Singh KP, Casado FL, Opanashuk LA and Gasiewicz TA. The aryl hydrocarbon receptor has a normal function in the regulation of hematopoietic and other stem/progenitor cell populations. *Biochem Pharmacol* 77:577-587, 2009.

Thomas K, MacIntosh S, Bannon G, Herouet-Guicheney C, Holsapple M, Ladies G, McClain S, Vieths S, Woolhiser M and Privalle L. Scientific advancement of novel protein allergenicity evaluation: an overview of work from the HESI Protein Allergenicity Technical Committee (2000-2008). *Food Chem Toxicol* 47:1041-1050, 2009.

Zelikoff JT. Other environmental health issues: Inhaled woodsmoke. In: *Encyclopedia of Environmental Health*. J. Nriagu (Ed.). Elsevier, UK. 2009.